<DOC>
	<DOCNO>NCT01101893</DOCNO>
	<brief_summary>In study , approximately 16 subject receive raltegravir 400mg twice daily 5 day ( Treatment A ) follow washout period . In Period 2 , subject receive GSK2248761 200mg daily 5 day ( Treatment B ) . There wash Period 2 3 . Subjects administer raltegravir 400mg twice daily combination GSK2248761 200mg daily ( Treatment C ) 5 day . Subjects house unit duration study . Safety evaluations serial PK sample collect treatment period . A follow-up visit occur 7-14 day last dose study drug .</brief_summary>
	<brief_title>A Drug Interaction Study Evaluating GSK2248761 Raltegravir Pharmacokinetics Healthy Adult Subjects</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , vital sign , laboratory test , ECGs . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 50 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Is premenopausal documented bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) hysterectomy , postmenopausal define 12 month spontaneous amenorrhea . A follicle stimulate hormone ( FSH ) level perform confirm postmenopausal status . For study , FSH level &gt; 40 MlU/ml confirmatory . Male subject must agree use one contraception method list Section 8.1 study protocol . This criterion must follow time first dose study medication followup visit . Body weight great equal 50 kg men great equal 45 kg woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . Note : One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . History regular use tobacco nicotinecontaining product within 3 month prior screen . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Note : include plasma donation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . AST , ALT , alkaline phosphatase bilirubin great equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Pregnant female determine positive serum hCG test screen prior dosing . Lactating female . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject Screening predose Day 1 . Cardiac conduction abnormality denote follow single 12lead ECG screen predose Day 1 ( single repeat allow eligibility determination ) Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) . Sinus Pauses &gt; 3 second . Any significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . Nonsustained sustain ventricular tachycardia ( great equal 3 consecutive ventricular ectopic beat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>GSK2248761 , raltegravir , drug interaction , pharmacokinetics</keyword>
</DOC>